Abstract
Ninety-eight patients with metastatic breast cancer, heavily pretreated with other agents, were entered in a phase II trial of hexamethylmelamine (HEX). Patients were randomized to receive HEX alone or combined with prophylactic pyridoxine. There was a 2% response rate in 89 partially or fully evaluable patients. Seven percent of these patients developed neurologic toxicity which occurred in the HEX-alone group only.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Aged
-
Altretamine / adverse effects
-
Altretamine / therapeutic use*
-
Breast Neoplasms / drug therapy*
-
Drug Evaluation
-
Female
-
Humans
-
Middle Aged
-
Nausea / chemically induced
-
Nervous System Diseases / chemically induced
-
Pyridoxine / therapeutic use
-
Triazines / therapeutic use*
Substances
-
Triazines
-
Pyridoxine
-
Altretamine